Gesynta Pharma ABWallingatan 24SE-111 24 Stockholm
info@gesynta.seLinkedIn
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.
Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.
Our lead drug candidate GS-248 is currently under evaluation in a phase 2 study.
We use cookies. By continuing to use the site, you agree to the use of cookies. Read more.